Nephrotic Syndrome Clinical Trial
Official title:
Fluid Balance, Hormones and Urine Proteomics in Nephrotic Syndrome in Childhood
The purpose of this study is to describe the hormones controlling fluid balance in pediatric patients with nephrotic syndrome. Further more, an analysis of the urinary and plasma proteins will be done using proteomics. Different composition of proteins in the urine or plasma might indicate if the patients will respond to treatment or not.
Nephrotic syndrome represents the association of proteinuria, hypoalbuminemia, oedema and
hyperlipidemia. The pathogenesis of the oedemas remains controversial. The "underfill"
theory is the traditional explanation where massive proteinuria leads to low plasma albumine
and a subsequent decrease in intravascular osmotic pressure leading to edema formations.
Because most patients are normotensive and have normal intravascular pressure the "overfill"
theory has been proposed suggesting a primary defect in renal sodium handling being
responsible for oedema formation.
Ten percent of the children with nephrotic syndrome do not respond to standard steroid
treatment and a significant proportion of these patients progress towards end-stage renal
failure. At initial presentation it cannot be said if a patient will respond to treatment or
not.
The purposes of the sudy:
1. To describe changes in the hormones, Aldosterone, Atrial Natriuretic Peptide (ANP),
Arginin Vasopressin (AVP), Renin and Angiotensin II in patients with idiopathic
nephrotic syndrome and to analyse to what extend the change in these hormones reflected
a "underfill" or "overfill" situation.
2. To describe changes in the urine concentration of the water channel AQP II and the
sodium channel ENaC during the course of nephrotic syndrome.
3. To test the hypothesis that urine and plasma proteomics from patients with steroid
resistant nephrotic syndrome differs from patients with steroid sensitive nephrotic
syndrome.
50 pediatric patients with nephrotic syndrome will be included after informed consent from
both parents.
At day 1, 2, 3, 30 and 120 blood samples for hormones will be taken together with creatinin,
albumine, Na+, K+, Hgb. An Echocardiography will be performed at day 1 and day 30 to
determine v. cava inferior index.
At day 1,30 and 120 urine and plasma will be collected for proteomics and measurement of AQP
II and ENaC concentrations.
Further more a clinical examination will be performed at day 1, 2, 3, 30 and 120 and weight,
blood pressure and response to treatment will be recorded.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02238418 -
Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
|
Phase 4 | |
Completed |
NCT01895894 -
Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome
|
Phase 4 | |
Completed |
NCT01411982 -
Role of PACAP in Nehprotic Syndrome
|
N/A | |
Recruiting |
NCT00308321 -
Long Term Tapering or Standard Steroids for Nephrotic Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03326037 -
Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East
|
||
Recruiting |
NCT01240564 -
The Nephrotic Syndrome Study Network (NEPTUNE)
|
N/A | |
Completed |
NCT01252901 -
Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases
|
N/A | |
Completed |
NCT01197040 -
Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome
|
Phase 3 | |
Terminated |
NCT00883636 -
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
|
N/A | |
Completed |
NCT00035334 -
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
|
Phase 2/Phase 3 | |
Terminated |
NCT00004466 -
Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
|
Phase 2 | |
Terminated |
NCT04558892 -
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
|
Phase 2/Phase 3 | |
Completed |
NCT02257697 -
A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
|
Phase 3 | |
Completed |
NCT00362531 -
Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT00289328 -
Glucocorticoid-induced Osteopenia in Children
|
N/A | |
Recruiting |
NCT04759274 -
Diuretic Tuner Clinical Decision Support
|
N/A | |
Completed |
NCT00001212 -
Drug Therapy in Lupus Nephropathy
|
Phase 2 | |
Recruiting |
NCT05623033 -
The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection
|
||
Completed |
NCT03332420 -
The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
|
||
Not yet recruiting |
NCT05904197 -
Effectiveness of Educational Gamified Cards About Nephrotic Syndrome
|
N/A |